ClinicalTrials.gg
RecruitingNCT06449989GENCONCOR-1Updated Oct 5, 2026

Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer

An observational study in Colorectal Cancer Metastatic, Brain Metastases, Adult and Ras (KRAS or NRAS) Gene Mutation, sponsored by Blokhin's Russian Cancer Research Center. Recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Blokhin's Russian Cancer Research Center · Observational

How we know · 3 judgments

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Brain Neoplasms with a site in Russia — 6 open to participants now, 9 under way, none of them phase 3. Brain Neoplasms · Russia.

Started
2024
the only one that year
Observational
4 of 10
2 open now
Registered
6th of 10
by date
Lead sponsor
4 of 10
Blokhin's Russian Cancer Research Center

Among the 10 studies in Brain Neoplasms with a site in Russia, this one is the only one that started in 2024, is one of 4 observational ones, and was the 6th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

6 of the 10 studies in Brain Neoplasms with a site in Russia are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Brain Neoplasms with a site in Russia, or all of them as a file.
02

Study summary

GENCONCOR-1 study is translational research aimed to investigate the concordance of the molecular genetic profile of the primary tumor and brain metastases (BM) of colorectal cancer (CRC). The study was conducted by post hoc analysis of pairs of samples of histological material with determination of the mutational status of genes KRAS, NRAS, BRAF, HER2 and MSI.

Read the detailed description

Brain metastases (BM) from colorectal cancer (CRC) are a rare event reported in less than 3% of patients with CRC (the reported incidence ranges from 0.27 to 3%). This course is associated with a poor prognosis. Treatment of these patients remains challenging. Nevertheless, given the rarity of the event, at this time not enough is known about molecular biology of BM from colorectal cancer and its concordance with matched primary tumors.

In N.N. Blokhin National Medical Research Center of Oncology over 26 years (1998-2024) identified 108 patients with BM from CRC. Of this number, 72 patients had a history of neurosurgical resection of BM. In turn, for 32 patients access to a pair of tumor samples: from the primary tumor and from intracranial metastases. Tumor samples will be tested for mutation status of genes KRAS, NRAS, BRAF, HER2 and MSI. Analysis was limited to this pool of genes because of their clinical relevance and potential prognostic information. The molecular profile of the BM will be compared with the corresponding primary tumor with calculation of concordance rate (%).

03

Conditions studied

  • Colorectal Cancer Metastatic
  • Brain Metastases, Adult
  • Ras (KRAS or NRAS) Gene Mutation
  • BRAF Gene Mutation
  • HER2 Gene Mutation
  • MSI

Browse trials for

Keywords

  • Colorectal Cancer Metastatic
  • Brain Metastases, Adult
  • Ras (KRAS or NRAS) Gene Mutation
  • BRAF Gene Mutation
  • HER2 Gene Mutation
  • MSI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with metastatic colorectal cancer (CRC) and brain metastases (BM) will be analyzed according to sex, age, functional status (ECOG 0-1 or 2-3), number of BM (solitary or ≥ 2), clinical manifestations of BM (symptomatic or asymptomatic), extracranial lesions at the time of diagnosis BM (present or absent), course of brain metastases (synchronous with the primary tumor or metachronous), side of the location of the primary tumor (left-sided or right-sided CRC), location of intracranial lesions (supratentorial or subtentorial), number of previous lines of drug therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women over 18 years of age.
  2. confirmed cancer of the colon or rectum.
  3. Histologically confirmed lesion of the brain.
  4. Neurosurgical resection for of colorectal cancer.
  5. Presence of paired tumor samples (both primary tumor and intracranial material).

Exclusion criteria

Exclusion Criteria:

  1. Missing one sample from a pair of tumor samples.
  2. Low quality or lack of tumor material for molecular genetic research.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Diagnostic testTumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI

    For molecular genetic research, archival formalin-fixed and paraffin-embedded tumor blocks will be used. Research method - HRM-PCR sequencing to determine mutation status of KRAS, NRAS and BRAF (RotorGene 6000, ABI Prism 3500) and fragmentation analysis to determine MSI (ABI Prism 3500) Subject to study: mutations in the KRAS, NRAS, BRAF genes, as well as MSI status and HER2neu expression (± amplification) Somatic mutations in the RAS family genes are planned to be studied in exons 2 (codons 12 and 13), exon 3 (codon 61) and exon 4 (codon 146). In the case of the BRAF gene - exon 15 (codons 597-601). Determination of microsatellite instability is planned using five markers: BAT25, BAT26, NR21, NR24, NR27, associated with structural and functional disorders of the DNA unpaired base repair system. Assessment of HER2 gene status is planned by immunohistochemical (IHC) screening of HER2neu expression. IHC-screening of HER2-status will be performed using an antibody clone 4B5 (Ventana).

06

What researchers measure

Primary outcomes

  1. Concordance rate (%)

    Concordance rate (%) between mutational status of the brain lesions and their corresponding primary tumor. Calculated as the ratio of concordant cases to total cases.

    Time frame: 1 month

Secondary outcomes

  1. Intracranial progression-free survival (CNS-PFS1)

    Time from the date of cancer diagnosis to the date of detection of brain metastases.

    Time frame: 3 months

  2. Overall survival (OS)

    Time from the date of detection of brain metastases to the date of death.

    Time frame: 6 months

  3. Intracranial progression-free survival (CNS-PFS2)

    Time from the date of neurosurgical resection to the date of intracranial progression (continued growth or distant brain metastases) or death.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Blokhin's Russian Cancer Research Center
    Moscow, Moscow 115478, Russia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underline the results reported in article, after deidentification (text, tables, figures, and appendices)

Time frame: From the moment of publication of the results and indefinitely

Access criteria: For individual participant data meta-analysis. Data will be available indefinitely in the appendix of the published article

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Sep 2027, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2024
First posted
Jun 10, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, responsible party and oversight details
1 update, last Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Minor edits only
    + 3 other changes: verification date, responsible party and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06449989
Lead sponsor
Blokhin's Russian Cancer Research Center
Responsible party
David Khalafyan (Physician-researcher, Blokhin's Russian Cancer Research Center) — Principal investigator
First posted
Jun 10, 2024
Start date
Apr 1, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

David Halafyan, MD
Contact
daveupnow@gmail.com
+7(930)928-00-72
Alexey Tryakin, MD, professor
study chair · Blokhin's Russian Cancer Research Center
Ali Bekyashev, MD, professor
study chair · Blokhin's Russian Cancer Research Center
Anna Stroganova, MD
study chair · Blokhin's Russian Cancer Research Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion